113 related articles for article (PubMed ID: 12416893)
1. Changes in serum ganglioside and antibody levels in soft tissue sarcoma: are they the cause or the effect of tumor progression?
Ferrone S
Cancer J; 2002; 8(5):369-70. PubMed ID: 12416893
[No Abstract] [Full Text] [Related]
2. Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications.
Perez CA; Ravindranath MH; Soh D; Gonzales A; Ye W; Morton DL
Cancer J; 2002; 8(5):384-94. PubMed ID: 12416896
[TBL] [Abstract][Full Text] [Related]
3. [Gangliosides and antibodies to gangliosides in blood serum].
Diatlovitskaia EV
Biokhimiia; 1992 Jul; 57(7):1004-10. PubMed ID: 1391209
[TBL] [Abstract][Full Text] [Related]
4. Serum total gangliosides and TA90-IC levels: novel immunologic markers in colorectal cancer.
Perez CA; Ravindranath MH; Gupta RK; Tollenaar RA; van de Velde CJ; Wood TF; Soh D; Morton DL; Bilchik AJ
Cancer J; 2002; 8(1):55-61. PubMed ID: 11898807
[TBL] [Abstract][Full Text] [Related]
5. Cryosurgical ablation of liver tumors in colon cancer patients increases the serum total ganglioside level and then selectively augments antiganglioside IgM.
Ravindranath MH; Wood TF; Soh D; Gonzales A; Muthugounder S; Perez C; Morton DL; Bilchik AJ
Cryobiology; 2002 Aug; 45(1):10-21. PubMed ID: 12445546
[TBL] [Abstract][Full Text] [Related]
6. Production of monoclonal antibodies directed to Hanganutziu-Deicher active gangliosides, N-glycolylneuraminic acid-containing gangliosides.
Watarai S; Kushi Y; Shigeto R; Misawa N; Eishi Y; Handa S; Yasuda T
J Biochem; 1995 May; 117(5):1062-9. PubMed ID: 8586620
[TBL] [Abstract][Full Text] [Related]
7. Ganglioside complexes as new target antigens in Guillain-Barré syndrome.
Kaida K; Morita D; Kanzaki M; Kamakura K; Motoyoshi K; Hirakawa M; Kusunoki S
Ann Neurol; 2004 Oct; 56(4):567-71. PubMed ID: 15389898
[TBL] [Abstract][Full Text] [Related]
8. Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma.
Casper ES; Cordon-Cardo C; Houghton AN; Steffens TA; McCormack P; Magill GB; Hajdu SI; Brennan MF
Cancer Invest; 1994; 12(1):20-5. PubMed ID: 8281462
[TBL] [Abstract][Full Text] [Related]
9. Serum gangliosides as endogenous immunomodulators.
Bergelson LD
Immunol Today; 1995 Oct; 16(10):483-6. PubMed ID: 7576052
[TBL] [Abstract][Full Text] [Related]
10. Low detection rate of p53 antibodies in sera of soft tissue sarcoma patients.
Würl P; Fittkau M; Meye A; Bartel F; Schmidt H; Schönfelder M; Taubert H
Cancer Lett; 2001 Sep; 170(2):199-205. PubMed ID: 11463499
[TBL] [Abstract][Full Text] [Related]
11. Ganglioside GD3 shedding by human gliomas.
Nakamura O; Iwamori M; Matsutani M; Takakura K
Acta Neurochir (Wien); 1991; 109(1-2):34-6. PubMed ID: 1648861
[TBL] [Abstract][Full Text] [Related]
12. Significance of endogenous augmentation of antiganglioside IgM in cancer patients: potential tool for early detection and management of cancer therapy.
Ravindranath MH; Muthugounder S; Hannah MR; Morton DL
Ann N Y Acad Sci; 2007 Jun; 1107():212-22. PubMed ID: 17804549
[TBL] [Abstract][Full Text] [Related]
13. Serum endostatin levels are elevated in patients with soft tissue sarcoma.
Feldman AL; Pak H; Yang JC; Alexander HR; Libutti SK
Cancer; 2001 Apr; 91(8):1525-9. PubMed ID: 11301401
[TBL] [Abstract][Full Text] [Related]
14. Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas.
Glorie N; Baert T; VAN DEN Bosch T; Coosemans AN
Anticancer Res; 2019 Aug; 39(8):3981-3989. PubMed ID: 31366479
[TBL] [Abstract][Full Text] [Related]
15. Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice.
Dumontet C; Rebbaa A; Portoukalian J
J Immunol Methods; 1997 Aug; 206(1-2):115-23. PubMed ID: 9328574
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
[TBL] [Abstract][Full Text] [Related]
17. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: new aspects of research.
Kusunoki S; Kaida K; Ueda M
Biochim Biophys Acta; 2008 Mar; 1780(3):441-4. PubMed ID: 17976386
[TBL] [Abstract][Full Text] [Related]
19. Gangliosides in serum immune complexes from tumor-bearing patients.
Håkansson L; Fredman P; Svennerholm L
J Biochem; 1985 Sep; 98(3):843-9. PubMed ID: 4086473
[TBL] [Abstract][Full Text] [Related]
20. Detection of Naturally Occurring Human Antibodies Against Gangliosides by ELISA.
Hernández AM; Rodríguez-Zhurbenko N
Methods Mol Biol; 2017; 1643():179-186. PubMed ID: 28667538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
